A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

NCT03406156 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)

Interventions

DRUG: Obinutuzumab
DRUG: Bendamustine
DRUG: Venetoclax

Sponsor

AbbVie